SBT8230 / ARS Pharma - LARVOL DELTA

Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021 (Businesswire) - "Silverback Therapeutics, Inc...announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2021. SBT8230 comprises a TLR8 agonist conjugated to an antibody specific to the liver-restricted receptor, ASGR1, and is designed to promote functional cures in chronic HBV (cHBV) through activation of an anti-viral immune response in a liver-localized manner...'We look forward to initiating Phase 1-enabling toxicology studies in the first quarter of 2022.'"

Preclinical • Hepatitis B • Infectious Disease

[VIRTUAL] SBT8230, AN ASGR1-DIRECTED TLR8 IMMUNOTAC THERAPEUTIC FOR THE TREATMENT OF CHRONIC HEPATITIS B VIRUS, DEMONSTRATES FAVORABLE PRECLINICAL TOLERABILITY WITH LIVER-LOCALIZED ACTIVITY (AASLD 2021) - "These preclinical studies confirm the MOA of SBT8230 and demonstrate that SBT8230 is well- tolerated and results in liver-localized activity in NHP . These studies support the continued preclinical development of SBT8230 for the treatment of cHBV."

Preclinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • FCGR2A • IFNG • TLR8

[VIRTUAL] Immunomodulatory Antibody Conjugates for the Treatment of Cancer & Chronic Viral Infections (ADC-USA 2021) - "Synopsis An overview of Silverback’s ImmunoTAC (Immunomodulatory Targeted Antibody Conjugate) technology platform Discussing the discovery and development of ImmunoTAC molecules containing a TLR8 agonist payload designed to stimulate local activation of myeloid cells Examining how broad and versatile potential of the ImmunoTAC platform is exemplified by oncology (SBT6050 and SBT6290) and virology (SBT8230) development candidates"

Immune Modulation • Infectious Disease • Inflammation • Oncology • TLR8

[VIRTUAL] SBT8230, an ASGR1-Directed TLR8 ImmunoTAC Therapeutic, is a Potent Myeloid Cell Agonist with Liver-Localized Activity for the Treatment of Chronic HBV (ADC-USA 2021) - "Understand the selection and optimization of TLR7/8 payloads Review the design of in vitro screening funnel for immune-activating ADCs Analyze results of direct and indirect lymphocyte activation studies Discuss how unexpected activity of noncleavable ADCs informs future strategy"

TLR7 • TLR8

Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates (Businesswire) - "SBT8230 (ASGR1-TLR8 ImmunoTAC) development candidate selected in the fourth quarter of 2020. SBT8230 includes the same TLR8 agonist linker-payload...conjugated to a proprietary ASGR1-directed monoclonal antibody, and is designed to activate human myeloid cells in the liver for treatment of chronic hepatitis B viral infection. CMC scale up and preclinical work continues with IND-enabling toxicology studies expected to commence in the first quarter of 2022."

Preclinical • Hepatitis B • Infectious Disease